Orasure Technologies Receives FDA Emergency Use Authorization for Ebola Rapid Diagnostic Test
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
OraSure Technologies (OSUR) Tops Q2 EPS by 2c
August 5, 2015 5:47 PM EDTOraSure Technologies (NASDAQ: OSUR) reported Q2 EPS of $0.03, $0.02 better than the analyst estimate of $0.01. Revenue for the quarter came in at $30.4 million versus the consensus estimate of $28.95 million.
"We are pleased with the record level of revenues reported for the second... More
OraSure Technologies (OSUR) Announces Receipt of FDA Emergency Use Authorization for OraQuick Ebola Test
August 3, 2015 6:48 AM EDTOraSure Technologies (NASDAQ: OSUR) announced that it has received a U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for its OraQuick Ebola Rapid Antigen Test for use with fingerstick and venous whole blood.
This test has not been cleared or approved by FDA. This test has been authorized by FDA under an EUA for use by laboratories and facilities adequately equipped, trained, and capable of testing for Ebola infection (including treatment centers and public health clinics).
The OraQuick® Ebola Rapid Antigen Test utilizes the OraQuick technology platform... More
